KORU Medical Systems, Inc.
KORU Medical Systems develops, manufactures, and commercializes portable large-volume subcutaneous infusion solutions used to deliver drugs under the FREEDOM Infusion System brand. Its products are designed for home and specialty-care administration of therapies such as immunoglobulin for PIDD and CIDP, and the company also supports pharma clinical trials and customization work for biopharmaceutical customers.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenuePortable syringe drivers and related devices used to infuse subcutaneous therapies.
Needle sets and tubing used with the FREEDOM System for recurring patient use.
Product supply and support for feasibility studies and clinical trial programs.
Customers
KORU sells mainly to specialty pharmacies, home infusion providers, pharmaceutical companies, and medical device distributors. These customers buy the FREEDOM System because it supports subcutaneous delivery of immunoglobulin and other therapies, often in home or ambulatory settings where portability and ease of use matter. The company also serves biopharma customers that need clinical-trial supply, testing, and customization support before broader commercialization.
Buy drivers, tubing, and needle sets for patients receiving immunoglobulin at home; they value one-stop purchasing and inventory management.
Purchase the FREEDOM System for subcutaneous drug administration in home-care settings where portability and patient convenience matter.
Resell KORU products and account for a large share of revenue; they matter because purchasing patterns can swing quarterly results.
Buy product supply and engineering support for feasibility studies, clinical trials, and commercialization readiness.
Use the system for subcutaneous drug delivery in clinical settings and outpatient care.
Strategy
KORU’s strategy centers on expanding adoption of the FREEDOM System in subcutaneous drug delivery while broadening its customer base beyond a small set of distributors. It is also investing in international expansion, new product introductions, and pharma-services relationships to diversify revenue and support longer-term growth.
A few distributors drive most revenue, so expanding channels lowers dependency and improves resilience.
Non-U.S. growth can diversify the business and increase the installed base of the FREEDOM System.
New devices and services help defend against competition and support biopharma commercialization.
Geography
Q1/2026KORU’s core business is split between domestic core revenue, which includes the U.S. and Canada, and international core revenue from markets outside North America. Manufacturing is concentrated in Mahwah, New Jersey, with additional contract manufacturing in Nicaragua for needle sets and tubing, making supply continuity and cross-border logistics important to execution.
Share of the revenue the company reports by geography.
Risks
KORU is exposed to customer concentration, distributor dependence, and competitive pressure in a medical-device market where larger peers and consolidating buyers can push pricing lower. Its business also depends on regulatory compliance, reimbursement dynamics, and uninterrupted manufacturing across its U.S. and Nicaragua supply chain.
- Distributor concentrationImpact: HighLikelihood: Medium
A small number of distributors account for most net revenue, so order timing and purchasing patterns can swing results.
Exposure: Three U.S. and six non-U.S. distributors represented about 77% of net revenues.
- Manufacturing and supply chain disruptionImpact: HighLikelihood: Medium
Production is split between Mahwah and Nicaragua, and any site outage or border/logistics issue could delay shipments.
Exposure: Needle sets and tubing rely on contract manufacturing in Nicaragua.
- Regulatory and reimbursement changesImpact: HighLikelihood: Medium
Demand depends on FDA clearance, payer coverage, and reimbursement for the therapies delivered with the system.
Exposure: Subcutaneous drug delivery and immunoglobulin therapy markets.
- Competitive and pricing pressureImpact: MediumLikelihood: Medium
Consolidation among medical device buyers and suppliers can increase bargaining power and force price reductions.
Exposure - Technology obsolescenceImpact: MediumLikelihood: Medium
If KORU fails to introduce new products or keep pace with infusion technology, customers may switch to alternatives.
Exposure: Mechanical infusion systems and accessories.
Accounting
Judgemental itemsSales are recorded when control transfers on shipment, so timing of distributor orders affects reported revenue.
Impact: Quarterly comparability
The syringe driver warranty creates expense recognition based on expected defect costs.
Impact: Gross margin and operating expense
Finished goods and components must be assessed for excess or obsolete stock as demand changes.
Impact: Working capital and cost of sales
Management notes possible future debt or equity financing if cash and operations are insufficient.
Impact: Capital structure and dilution risk
Similar listed companies
Publicly listed companies with a comparable business focus.
InfuSystem Holdings, Inc
INFU · Surgical & Medical Instruments & Apparatus
Corbus Pharmaceuticals Holdings, Inc.
CRBP · Pharmaceutical Preparations
Korro Bio, Inc.
KRRO · Pharmaceutical Preparations
Oramed Pharmaceuticals Inc
ORMP · Pharmaceutical Preparations
iRadimed Corporation
IRMD · Surgical & Medical Instruments & Apparatus
IRADIMED Corp designs and sells MRI-compatible medical devices used inside scanner rooms, centered on infusion pumps, patient vital signs monitoring systems, and related disposables and service.
OraSure Technologies, Inc
OSUR · Surgical & Medical Instruments & Apparatus
OraSure Technologies is a U.S.-based diagnostics and specimen-collection company that develops, manufactures, markets, and sells rapid tests and related collection devices.
Last updated: 24/09/2026